Status:

COMPLETED

Supplementation Trial on Arginine With Metabolic Profiling

Lead Sponsor:

Pennington Biomedical Research Center

Collaborating Sponsors:

Jennifer C. Rood

Robbie A. Beyl

Conditions:

Protein

Amino Acid

Eligibility:

MALE

18-39 years

Phase:

NA

Brief Summary

This study will assess effects of an acute dose of the amino acid arginine on metabolism in healthy young men.

Detailed Description

A double - blind randomized, crossover design trial examining arginine vs. placebo beverage treatments will be performed. The primary objective is to determine the effects of arginine assessed by stan...

Eligibility Criteria

Inclusion

  • BMI 18.5 - 25 kg/m2.
  • Must be physically active (exercise at least 2 days/week).
  • Willing to refrain from alcohol and supplements for the duration of the study.
  • Willing to refrain from supplement ingestion, nuts, watermelon, and cracklins (fatback) for the 2 weeks prior to the initial treatment diet through the duration of the study.

Exclusion

  • HIV or AIDS
  • Uncontrolled CVD/arrhythmia
  • Type I or type II diabetes
  • Pregnancy (or breastfeeding)
  • Diagnosed eating disorder
  • Non-normal sleeping patterns
  • Chronic neurological condition
  • Altered metabolism including growth hormone disorders
  • Use of nicotine or tobacco products
  • Heavy caffeine use (≥ 350 mg caffeine/d)
  • Whole blood donation within previous eight weeks
  • Protein supplementation
  • Protein wasting disease.
  • Exclusionary medications include diuretics, beta-blockers, weight loss medications or diet pills, anti-inflammatory drugs (corticosteroid/ anabolic steroid/NSAID), antipsychotic medication or other medication that may affect fluid balance, metabolism, or body weight.
  • Prisoners and adults who are unable to consent will be excluded from the study.
  • Lastly any other medical, psychiatric, or behavioral factors in the judgement of the Principle Investigator that may interfere with study participation or the ability to follow the protocol.

Key Trial Info

Start Date :

February 8 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 8 2019

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT03409380

Start Date

February 8 2018

End Date

July 8 2019

Last Update

September 14 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States, 70808